PMA P020050S043

Device
WaveLight EX500 Laser
Applicant
Alcon Laboratories, Inc.
Product code
LZS
Decision date
2025-03-05
Generic name
Excimer laser system
Approval order statement
Approval for the WaveLight EX500 laser system, in conjunction with INNOVEYES Sightmap, is indicated for use in INNOVEYES Laser Assisted In-Situ Keratomileusis (“wavelight plus” LASIK) treatments:• for the reduction or elimination of myopia or myopia with astigmatism, in eyes with spherical equivalent (SE) more than -1.00 and up to -9.00 diopters (D), with up to -8.00 D of spherical component (in minus cylinder format) and up to -3.00 D of astigmatic component at the spectacle plane, based on the INNOVEYES Sightmap Measured Refraction,• in patients with magnitude of the spherical equivalent (SE) difference between the Manifest Refraction (MRSE) and the Sightmap measured refraction SE being less than 0.75D,• in patients who are 18 years of age or older, and• for patients with documentation of a stable manifest refraction defined as </= 0.5 D preoperative spherical equivalent shift over one year prior to surgery.

Current openFDA PMA Record

Device
WaveLight EX500 Laser
Applicant
Alcon Laboratories, Inc.
PMA number
P020050
Supplement
S043
Product code
LZS
Generic name
Excimer laser system
Decision date
2025-03-05
Decision code
APPR
Date received
2023-10-31
Supplement type
Panel Track
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Approval order statement
Approval for the WaveLight EX500 laser system, in conjunction with INNOVEYES Sightmap, is indicated for use in INNOVEYES Laser Assisted In-Situ Keratomileusis (“wavelight plus” LASIK) treatments:• for the reduction or elimination of myopia or myopia with astigmatism, in eyes with spherical equivalent (SE) more than -1.00 and up to -9.00 diopters (D), with up to -8.00 D of spherical component (in minus cylinder format) and up to -3.00 D of astigmatic component at the spectacle plane, based on the INNOVEYES Sightmap Measured Refraction,• in patients with magnitude of the spherical equivalent (SE) difference between the Manifest Refraction (MRSE) and the Sightmap measured refraction SE being less than 0.75D,• in patients who are 18 years of age or older, and• for patients with documentation of a stable manifest refraction defined as

Related Records